JUNSHI BIO (01877.HK) elected Li Zhongxian and Lu Kun as independent non-executive Directors.

On December 20, Gelonghui reported that JUNSHI BIO (01877.HK) announced that the Board of Directors is pleased to announce that the resolution regarding the election of Li Zhongxian as an independent non-executive director has been approved at the extraordinary general meeting of shareholders held on December 20, 2024. The election of Li Zhongxian as an independent non-executive director became effective on the day of the extraordinary general meeting (i.e., December 20, 2024). The resolution regarding the election of Lu Kun as an independent non-executive director has also been approved at the extraordinary general meeting of shareholders held on December 20, 2024.

Gelonghui FinanceDec 20 21:59

Express News | The USA Biological Security Act was not included in the CR bill.

BreakingsDec 18 15:53

Sprint A+H! Maiwei Biotech plans to go public in Hong Kong through an IPO, but three products struggle to turn around the deficit situation.

① After nearly 3 years of being listed on the Star, Maiwei Bio plans to go public in Hong Kong, aiming to meet the funding needs of its Operation and to enhance its level of internationalization. ② Currently, Maiwei Bio has 3 commercial products, but the income from these products is insufficient to cover the huge research and development expenses as well as other shipping costs, leaving Maiwei Bio in a serious financial deficit.

cls.cnDec 16 16:44

Express News | Shanghai aims to nurture around 10 internationally competitive listed companies in key industries such as integrated circuits, biomedical, and new materials by 2027, forming a merger and acquisition trade scale of 300 billion yuan.

BreakingsDec 10 15:15

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 9 12:10

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 16:48